

Sanofi continues streamlining of established products with sale of dental care brands to Septodont

POSTED ON JULY 22, 2021

Sanofi has concluded an agreement to divest an integrated portfolio of dental care brands and related medical devices to Septodont, a French privately-owned company headquartered near Paris.

Divested portfolio includes four dental care brands Ultracain[®], Rodogyl[®], Birodogyl[®] and Dontisolon[®], as well as related medical devices, mostly marketed in Europe. This portfolio of high-quality medicines benefits patients both during and after dental operations, while covering most dental indications (anesthetics, anti-infective and anti-inflammatory).

This transaction continues Sanofi's ongoing strategic transformation announced in December 2019.

The agreement covers the registrations, trademarks, and related commercial rights. This is an asset deal. No employees, equipment or real estate is included.

Commercial terms of the agreement will not be disclosed.

About Septodont

Septodont is a leading manufacturer of dental pharmaceuticals and medical devices. Since its inception in 1932, the group develops, produces and distributes a large range of products and solutions dedicated to serving the needs of dental professionals across the world. The group counts 1,900 employees and has a long-established presence in more than 150 countries. Beyond dental and through its Novocol Pharma division, the group also partners with pharmaceutical and medical device companies to provide contract manufacturing services for pharmaceutical products that require cartridge filling. Learn more about Septodont's innovative, safe and healthcare solutions at <https://www.septodontcorp.com/>.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi Media Relations Contact

Sandrine Guendoul
Tel.: +33 (0)6 25 09 14 25
sandrine.guendoul@sanofi.com

Sanofi Investor Relations – Paris

Eva Schaefer-Jansen
Arnaud Delepine
Nathalie Pham

Sanofi Investor Relations – North America

Felix Lauscher
Fara Berkowitz
Suzanne Greco

Sanofi IR main line:

Tel.: +33 (0)1 53 77 45 45
investor.relations@sanofi.com
<https://www.sanofi.com/en/investors/contact>

Additional Septodont information for journalists

Aïcha Goudiaby
Chief HR & Communications Officer
Tel.: +33 (0)6 45 70 04 43

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly, and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.